IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
Go back to IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance| (NASDAQ: ICCM) | Delayed: 2.23 +0.03 (1.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.20 | 52 Week High | $ | |||
| Open | $2.20 | 52 Week Low | $ | |||
| Day High | $2.25 | P/E | N/A | |||
| Day Low | $2.13 | EPS | $ | |||
| Volume | 58,440 | |||||

